May 04, 2022
PROTAC diastereomer Design（negative control）
- boc.protac 1
- 1BOC Sciences
- PROTAC
Protocol Citation: boc.protac 2022. PROTAC diastereomer Design（negative control）. protocols.io https://dx.doi.org/10.17504/protocols.io.e6nvwk8o7vmk/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it’s working
Created: May 04, 2022
Last Modified: May 04, 2022
Protocol Integer ID: 61938
Keywords: protac drug development, pharmacokinetic characteristics of the isomer, molecular drug discovery, small molecular drug discovery, mixture of diastereomer, protac diastereomer, new drug discovery goal, drug discovery, protac diastereomer to customer, pharmacokinetic, service provider in drug discovery, biotransformation, pharmacokinetic characteristic, individual isomer, single diastereomer, drug development, diastereomer, drug interaction, relationship between molecule, molecule, isomer, protac, dose linearity, boc science, vivo, metabolic, stereoisomer, samples from the early stage
Abstract
Diastereomers are stereoisomers in which molecules have two or more chiral centers and the relationship between molecules is not mirrored. In PROTAC drug development, in order to evaluate the pharmacokinetics of a single diastereomer or mixture of diastereomers, manufacturers should quantitatively analyze samples from the early stages of drug development for a single diastereomer in vivo. This will allow the assessment of the possibility of mutual transformation as well as the distribution of absorption, distribution, biotransformation and excretion (ADBE) of individual isomers. When the drug is a raceme and the pharmacokinetic characteristics of the isomers are different, the manufacturer should monitor the diastereomer separately to determine properties such as dose linearity and the effects of metabolic or excretory changes and drug-drug interactions.
As a leading service provider in drug discovery and development, BOC Sciences is fully qualified and committed to providing one-stop PROTAC®development services, which has become a promising strategy in the field of small molecular drug discovery. With a comprehensive and advanced platform, we design PROTAC diastereomer to customers around the world to meet new drug discovery goals.
Troubleshooting